IMJUDO is associated with a range of immune-mediated and infusion-related adverse events, some of which may be severe or life-threatening.

Adverse Reaction Profile of IMJUDO Combination Therapy

The most common adverse reactions (≥20%) observed with IMJUDO and durvalumab include rash, diarrhea, fatigue, pruritus, musculoskeletal pain, and abdominal pain. Laboratory abnormalities frequently involve elevated AST, ALT, decreased hemoglobin, sodium, increased bilirubin, alkaline phosphatase, and decreased lymphocytes. Serious immune-mediated events such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, and pancreatitis can occur, sometimes requiring permanent discontinuation. Infusion-related reactions and embryo-fetal toxicity are also notable risks. The safety profile in pediatric patients is not specified in the description.